137 related articles for article (PubMed ID: 15519796)
1. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
Siemann DW; Shi W
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1233-40. PubMed ID: 15519796
[TBL] [Abstract][Full Text] [Related]
2. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
Shi W; Siemann DW
In Vivo; 2005; 19(6):1045-50. PubMed ID: 16277020
[TBL] [Abstract][Full Text] [Related]
3. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):846-53. PubMed ID: 15936569
[TBL] [Abstract][Full Text] [Related]
4. In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.
Varghese HJ; Mackenzie LT; Groom AC; Ellis CG; Ryan A; MacDonald IC; Chambers AF
Angiogenesis; 2004; 7(2):157-64. PubMed ID: 15516836
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of radiation response with the vascular targeting agent ZD6126.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
Medinger M; Esser N; Soltau J; Lehmann KM; Konerding MA; Wolloscheck T; Ryan AJ; Drevs J
Int J Oncol; 2011 Feb; 38(2):455-64. PubMed ID: 21152862
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1512-7. PubMed ID: 12459379
[TBL] [Abstract][Full Text] [Related]
9. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Nicholson B; Gulding K; Conaway M; Wedge SR; Theodorescu D
Clin Cancer Res; 2004 Dec; 10(24):8728-34. PubMed ID: 15623658
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
11. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
Drevs J; Konerding MA; Wolloscheck T; Wedge SR; Ryan AJ; Ogilvie DJ; Esser N
Angiogenesis; 2004; 7(4):347-54. PubMed ID: 15886878
[TBL] [Abstract][Full Text] [Related]
12. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
Wachsberger PR; Burd R; Marero N; Daskalakis C; Ryan A; McCue P; Dicker AP
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):835-42. PubMed ID: 15701874
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):164-71. PubMed ID: 12007956
[TBL] [Abstract][Full Text] [Related]
14. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
[TBL] [Abstract][Full Text] [Related]
15. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Martinelli M; Bonezzi K; Riccardi E; Kuhn E; Frapolli R; Zucchetti M; Ryan AJ; Taraboletti G; Giavazzi R
Br J Cancer; 2007 Oct; 97(7):888-94. PubMed ID: 17848949
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Siemann DW; Shi W
Anticancer Res; 2008; 28(4B):2027-31. PubMed ID: 18751370
[TBL] [Abstract][Full Text] [Related]
17. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Rich JN; Sathornsumetee S; Keir ST; Kieran MW; Laforme A; Kaipainen A; McLendon RE; Graner MW; Rasheed BK; Wang L; Reardon DA; Ryan AJ; Wheeler C; Dimery I; Bigner DD; Friedman HS
Clin Cancer Res; 2005 Nov; 11(22):8145-57. PubMed ID: 16299247
[TBL] [Abstract][Full Text] [Related]
18. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
Goto H; Yano S; Zhang H; Matsumori Y; Ogawa H; Blakey DC; Sone S
Cancer Res; 2002 Jul; 62(13):3711-5. PubMed ID: 12097279
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]